Roka Bioscience Closes on $27.5M of Targeted $47.5M in Series D Round | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roka Bioscience said after the close of the market on Friday that it has raised $27.5 million toward a $47.5 million Series D financing round.

It closed on $27.5 million of the round in December and said it expects to close on the remaining $20 million later this year. Proceeds will go toward commercialization of its Atlas System and ongoing assay development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.